Innohep® (Tinzaparin Sodium)

Innohep (tinzaparin sodium) acts within the anticoagulation pathway to prevent and treat venous thromboembolism.

• Prophylaxis of deep vein thrombosis (DVT) in orthopedic surgery patients: reduces postoperative clot formation after procedures such as hip or knee replacement.
• Treatment of acute deep vein thrombosis: accelerates resolution of existing clots in the deep venous system.
• Treatment and secondary prevention of pulmonary embolism: helps dissolve emboli and prevents recurrence.
• Prevention of clot formation in patients undergoing hemodialysis: maintains circuit patency during dialysis sessions.

• Tinzaparin sodium binds to antithrombin III, enhancing its inhibitory activity against activated factor X (Xa) and, to a lesser extent, factor IIa (thrombin). This selective inhibition disrupts the conversion of prothrombin to thrombin and the generation of fibrin, thereby reducing clot formation while preserving a more predictable anticoagulant profile than unfractionated heparin.

Tinzaparin sodium may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Injection site erythema or pain: mild local irritation at the subcutaneous site.
• Minor bleeding or bruising: occasional superficial hemorrhage.
• Thrombocytopenia: modest reduction in platelet count.
• Nausea or gastrointestinal discomfort: transient upset.

Serious or Rare Side Effects

• Major bleeding: potentially life‑threatening hemorrhage in critical sites.
• Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet activation leading to paradoxical clotting.
• Spinal or epidural hematoma: bleeding in the neuraxial space after regional anesthesia.
• Severe allergic reaction: anaphylaxis or angioedema.
• Acute adrenal hemorrhage: rare internal bleeding affecting adrenal glands.

When using Innohep, clinicians should observe several precautionary measures to minimize risk.

• Renal function assessment: adjust use in patients with severe renal impairment.
• Platelet monitoring: check for heparin‑induced thrombocytopenia during therapy.
• Bleeding risk evaluation: avoid in active bleeding or recent major surgery.
• Dose adjustment in elderly or low body weight: consider reduced dose based on clinical judgment.
• Concomitant anticoagulant avoidance: limit use with other anticoagulants or antiplatelet agents.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tinzaparin sodium can interact with other medicines, influencing its anticoagulant effect.

Major Interactions (Avoid)

• Other anticoagulants (e.g., warfarin, direct oral anticoagulants): markedly increased bleeding risk.
• Antiplatelet agents (e.g., aspirin, clopidogrel): additive antithrombotic effect.
• Spinal or epidural anesthesia/neuraxial procedures: risk of spinal hematoma.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may enhance bleeding.
• Corticosteroids: potential for gastrointestinal bleeding.